Modulating the endocannabinoid system in alcohol use disorder: A translational systematic review and meta-analysis of preclinical and human studies.
A comprehensive systematic review examining CBD alcohol use disorder treatment potential found that CBD consistently reduced alcohol consumption in preclinical studies. However, human clinical data remains insufficient to support treatment…
Associations of cannabis use, other substances, and lifestyle choices on anxiety in medical cannabis patients across 45 days.
Previous research has shown medical cannabis (MC) to help reduce anxiety for some individuals, although most studies show trends using cross-sectional design...
From Analgesia to Synaptic Remodeling: A Systematic Review of Acetaminophen’s Neuromodulatory Effects.
Neuro-related disorders will be rising globally. Current treatments have numerous limitations that can impair patients' quality of life. One of the key thera...
A sesquiterpene-rich essential oil from Cannabis sativa L. attenuates symptoms and neuroinflammation in experimental autoimmune encephalomyelitis model through a CB2-mediated signalling.
Researchers found that cannabis essential oil neuroinflammation reduction occurred through CB2 receptor activation in an experimental multiple sclerosis model. The sesquiterpene-rich formulation improved pain, motor function, and emotional symptoms…
Relationship of Ethanol, Cannabinoids, Benzodiazepines, and Opioids to Serious Injuries from Falls in Adults Aged 55 and Older.
A trauma center study of 274 adults over 55 found that cannabis use and falls in elderly adults was not associated with increased injury severity. This objective toxicological data challenges assumptions about cannabis-related fall risk and provides…
Highly purified cannabidiol (CBD) in CDKL5 deficiency disorder (CDD): Open-label prospective study.
A new open-label study examining CBD for CDKL5 deficiency disorder treatment found 89% of patients continued therapy for 12 months. While retention rates suggest tolerability, efficacy data remains limited in this rare developmental epilepsy condition.
Defining Cannabis Use Disorder in Administrative Health Data: A Systematic Review of Case Definitions and Validation Approaches.
A systematic review of 56 studies reveals concerning inconsistencies in how cannabis use disorder administrative data validation occurs across health systems. Most studies used ICD diagnostic codes without proper validation, undermining the reliability…
Cannabis and Mental Health: A Review.
A comprehensive JAMA review reveals the stark gap between widespread cannabis use for mental health conditions and actual clinical evidence. While patients commonly self-medicate with cannabis for psychiatric symptoms, this systematic analysis found…
Prevalence and Correlates of Symptoms of Cannabinoid Hyperemesis Syndrome in the United States.
A groundbreaking national survey reveals cannabinoid hyperemesis syndrome prevalence affects nearly 1 in 5 daily cannabis users. This first population-level study provides critical data for clinicians treating cannabis-related health issues. The findings…
Canadian real-world evidence: observational 24-week outcomes for health care practitioner authorized cannabis.
A large Canadian observational study demonstrates medical cannabis real world effectiveness across chronic pain, anxiety, and sleep disorders over 24 weeks. This real-world evidence provides clinicians with practical outcome expectations for sustained…
